Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Launched by TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER · Jun 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Avmacol ES to see if it can help prevent heart and blood vessel problems that often come with aging. Specifically, the researchers want to find out if a compound called SFN can be safely given to people over 60 years old, especially those who have heart failure with preserved ejection fraction (HFpEF), meaning their heart pumps normally but still causes symptoms. The study will assess how well this treatment works by using heart ultrasound tests and measuring exercise endurance at the beginning and after 24 weeks.

To participate, individuals need to be 60 years or older, able to walk more than 500 feet, and willing to stop taking certain over-the-counter supplements during the study. However, people with certain conditions, like active cancer, or those who can't understand the study materials in English, cannot take part. Participants can expect to have their heart health monitored closely and may help researchers learn more about how to protect the heart as we age.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 60 years
• • Diagnosis of HFpEF (HF symptoms with a normal EF (\>/=50 %)
• • Ability to walk more than 500 feet (by self-report)
• • Willing to avoid taking all over the counter antioxidant phytochemical supplements (vegetable or fruit-containing supplement pills) during the study
• Exclusion Criteria:
• • Inability to provide informed consent
• • Diagnosis of active cancer
• • Inability to read and understand the SF-36 in English
• • Participants using over the counter antioxidant supplements
• • Participants with pulmonary or other issues which restrict walking capacity
• • On oxygen therapy